Alpha Teknova Charts Cautious Path to 2027 Growth

Alpha Teknova, Inc. ((TKNO)) has held its Q1 earnings call. Read on for the main highlights of the call.

Alpha Teknova, Inc. struck an upbeat tone in its latest earnings call, highlighting a return to double‑digit revenue growth, sharper gross margins, and early benefits from operational scaling. Management balanced this optimism with candor about ongoing GAAP losses, negative adjusted EBITDA, and reliance on a recovering biotech funding environment before profitability can firmly take hold.

Revenue Rebounds as Q1 Tops $11 Million

Total revenue rose 13% year over year, marking the first first‑quarter in nearly three years that Alpha Teknova exceeded $11 million in sales. Management framed this as evidence that demand is gradually normalizing after a difficult funding cycle for customers in the life sciences sector.

Clinical Solutions Delivers an 85% Growth Surge

Clinical Solutions revenue jumped 85% to $2.1 million, up from $1.2 million, fueled by more customers and higher average revenue per account. Executives stressed that the gains were broad‑based rather than driven by a single large order, suggesting a healthier, more diversified pipeline.

Lab Essentials Posts Modest but Stable Gains

Lab Essentials, the company’s core consumables business, generated $8.4 million in revenue, a 3% increase from $8.1 million a year earlier. The segment benefited from higher average revenue per customer even as the total customer count declined, indicating some softness in research‑stage demand.

Margins Improve as Profitability Metrics Tighten

Gross profit climbed to $3.8 million from $3.0 million, lifting gross margin to 34.2% from 30.7% in the prior‑year quarter. Adjusted EBITDA remained negative at $2.0 million but improved from a loss of $2.5 million, reflecting better cost control and higher volumes through the plant.

Cash Flow and Balance Sheet Show Gradual Progress

Free cash outflow improved to $3.6 million from $4.3 million, representing roughly a 16% year‑over‑year improvement. The company ended the quarter with $17.8 million in cash, cash equivalents, and short‑term investments, offset by $13.2 million in total borrowings.

Operational Upgrades Aim to Scale Efficiently

Alpha Teknova reported key operational enhancements, including tripling the single‑batch size for high‑volume bottle production to spread fixed costs over more units. It also deployed an automated aseptic filling line and began digitizing paper batch records, measures aimed at boosting throughput, analytics, and standardization while cutting labor hours per unit.

Commercial Spend Ramps to Support 2027 Growth Target

The company is increasing annual commercial spending by roughly $2 million starting in 2026, focused on sales and marketing resources. Management expects these investments to translate into higher lead generation and field coverage, with a goal of driving about 20% revenue growth in 2027.

2026 Guidance Reaffirmed Despite Strong Start

Executives reiterated 2026 revenue guidance of $42 million to $44 million, with the midpoint implying about 6% growth over 2025 and full‑year gross margins in the mid‑30s. Free cash outflow is expected to remain under $10 million even with heavier commercial investment, signaling a controlled approach to spending.

Net Loss Persists as Company Remains Unprofitable

Alpha Teknova posted a net loss of $4.6 million, or negative $0.08 per diluted share, essentially unchanged from a $4.6 million loss and negative $0.09 per share a year ago. The figures underscore that the business has yet to achieve GAAP profitability despite improving top‑line and margin trends.

Adjusted EBITDA Still Below Break‑Even

Adjusted EBITDA remained in the red at negative $2.0 million, though this marked progress versus the prior year’s negative $2.5 million. Management suggested that reaching adjusted EBITDA profitability would require annualized revenue in the range of roughly $52 million to $57 million, with a target of delivering at least one positive quarter by 2027.

Lab Essentials Growth Slows Amid Customer Attrition

While Lab Essentials revenue edged higher, its 3% growth rate and fewer customers raise questions about underlying demand in certain research‑driven markets. The company is leaning on higher wallet share among remaining customers to offset this attrition, but investors may watch closely for signs of renewed volume growth.

High Fixed Costs Shape Marginal Cash Dynamics

Management estimated that each incremental dollar of revenue converts to cash at a marginal rate of about 70%, highlighting the benefits of scale in a fixed‑cost heavy model. However, this structure also means that near‑term cash flow improvements rely heavily on sustained volume gains, adding execution risk if demand wavers.

Conservative Outlook Amid Macro and Funding Uncertainty

Despite the strong first quarter, leadership struck a cautious tone, citing macro uncertainty and the need for more evidence of durable large orders before lifting guidance. The company emphasized that its recovery trajectory is closely tied to biotech funding trends, which tend to flow through customer spending with a multi‑quarter lag.

Seasonality and Order Lumpiness Remain a Watchpoint

Alpha Teknova warned that quarterly results may remain lumpy, particularly in Clinical Solutions where average order sizes are larger and timing can be uneven. Even though Q1 growth appeared broad‑based, this inherent volatility could complicate forecasting and near‑term visibility for investors.

Working Capital and Cash Runway Under the Microscope

With $17.8 million in cash and $13.2 million in borrowings, the company’s balance sheet provides some, but not ample, flexibility for its strategic plans. Management’s commitment to keeping 2026 free cash outflow under $10 million underscores the importance of disciplined working capital and measured investment if macro conditions deteriorate.

Guidance Points to Gradual Progress Toward Profitability

Forward‑looking guidance calls for modest revenue growth in 2026, mid‑30s gross margins, and controlled cash burn despite stepped‑up commercial spending. Coupled with operational efficiencies and a targeted revenue range for adjusted EBITDA break‑even, the company is signaling a measured path to improved profitability by 2027, albeit one dependent on market tailwinds.

Alpha Teknova’s latest earnings call painted the picture of a company rebuilding momentum, with Clinical Solutions leading growth and margins trending higher. Yet persistent losses, modest Lab Essentials expansion, and a thin cash cushion leave little room for missteps, making execution and the broader funding backdrop critical for investors tracking the story.